Table 1.
Patient characteristics at time of marginal zone lymphoma diagnosis.
| All patients | Transformed | Non-transformed | p-value | ||||
|---|---|---|---|---|---|---|---|
| n = 1793 | n = 75 | n = 1718 | |||||
| Female, no (%) | 914 | (51) | 38 | (51) | 876 | (51) | 0.96 |
| Age >60, no (%) | 1256 | (70) | 50 | (67) | 1206 | (70) | 0.51 |
| Age, median (range) | 68 | (18–97) | 65 | (18–87) | 68 | (18–97) | <0.05 |
| MZL subtype, no (%) | <0.001 | ||||||
| Extranodal | 990 | (55) | 22 | (29) | 968 | (56) | |
| Nodal | 537 | (30) | 41 | (55) | 496 | (29) | |
| Splenic | 266 | (15) | 12 | (16) | 254 | (15) | |
| Ann Arbor stage, no (%) | <0.001 | ||||||
| I | 697 | (39) | 12 | (16) | 685 | (40) | |
| II | 200 | (11) | 14 | (19) | 186 | (11) | |
| III | 130 | (7) | 15 | (20) | 115 | (7) | |
| IV | 715 | (40) | 34 | (45) | 681 | (40) | |
| Unknown | 51 | (3) | 0 | (0) | 51 | (3) | |
| LDH, no (%) | <0.001 | ||||||
| Normal | 1335 | (74) | 47 | (63) | 1288 | (75) | |
| Elevated | 294 | (16) | 26 | (35) | 268 | (16) | |
| Unknown | 164 | (9) | 2 | (3) | 162 | (9) | |
| Extranodal sites, no (%) | 0.38 | ||||||
| <2 | 1505 | (84) | 63 | (84) | 1442 | (84) | |
| ≥2 | 249 | (14) | 12 | (16) | 237 | (14) | |
| Unknown | 39 | (2) | 0 | (0) | 39 | (2) | |
| WHO performance score, no (%) | 0.79 | ||||||
| <2 | 784 | (44) | 30 | (40) | 754 | (44) | |
| ≥2 | 51 | (3) | 2 | (3) | 49 | (3) | |
| Unknown | 958 | (54) | 43 | (57) | 915 | (53) | |
| IPI-score, no (%)a | <0.01 | ||||||
| ≤2 | 1264 | (71) | 51 | (68) | 1213 | (71) | |
| >2 | 313 | (17) | 22 | (29) | 291 | (17) | |
| Unknown | 216 | (12) | 2 | (3) | 214 | (12) | |
| Treatment group, no (%) | |||||||
| No treatment | 917 | (51) | 40 | (53) | 877 | (52) | <0.01 |
| Radiotherapy only | 384 | (21) | 4 | (5) | 380 | (22) | |
| Rituximab monotherapy | 70 | (4) | 3 | (4) | 67 | (4) | |
| (Immuno)chemotherapy | 402 | (22) | 27 | (36) | 375 | (22) | |
| Other/unknown | 20 | (1) | 1 | (1) | 19 | (1) | |
MZL marginal zone lymphoma, LDH lactate dehydrogenase, IPI-score International Prognostic Index score.
*Statistically significant P-vales (P-value <0.05) are presented in bold.
aMissing WHO performance scores were scored as 0 for the calculation of the IPI-score.